Skip to main content
Erschienen in: Skeletal Radiology 1/2021

03.07.2020 | Scientific Article

Marrow uptake on FDG PET/CT is associated with progression from smoldering to symptomatic multiple myeloma

verfasst von: Behrang Amini, Yves-Paul N. Nakache, Lorenzo Nardo, Elisabet E. Manasanch, Jia Sun, Leon Lenchik, Robert D. Boutin

Erschienen in: Skeletal Radiology | Ausgabe 1/2021

Einloggen, um Zugang zu erhalten

Abstract

Objective

To determine association of body composition measurements on CT and PET with progression of smoldering myeloma to multiple myeloma.

Methods

A retrospective cohort study in 65 patients with smoldering myeloma and PET/CT at diagnosis was performed at a tertiary cancer center. Subjects were between 38 and 87 years of age (mean 64) and included 37 males. Primary outcome was progression-free survival as a function of bone, fat, and muscle metrics on CT and PET (measured at the level of L4 pedicles) and clinical confounders. CT metrics included attenuation of L4 and retroperitoneal fat and various indices derived from the psoas muscle. PET measures included SUVmax and SUVmean of L4, retroperitoneal fat, and psoas. Cox proportional hazards modeling was performed with entry and retention criteria of p < 0.1 and p < 0.05, respectively.

Results

SUVmax and SUVmean were associated for each compartment (R2 = 0.78–0.84), and SUVmean (SUV) was used for subsequent analyses. SUV of the L4 vertebral body was associated with attenuation of the L4 vertebral body (p = 0.0032). There was no association between SUV and CT for muscle and fat compartments. In the subset of patients with bone marrow biopsy results (n = 43), there was no association between SUV of L4 and plasma cell concentration on core biopsy or flow cytometry (p = 0.089 and 0.072, respectively). The final Cox model showed association with albumin (HR 0.29, 95%CI 0.088–0.93, p = 0.038), M protein (HR 1.31, 95%CI 1.021–1.68, p = 0.034), and SUV of L4 (HR 1.99, 95%CI 1.037–3.82, p = 0.039).

Conclusion

SUV of L4 is a prognostic indicator in patients with smoldering myeloma.
Literatur
1.
Zurück zum Zitat Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69(1):7–34.CrossRef Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69(1):7–34.CrossRef
2.
Zurück zum Zitat Landgren O, Kyle RA, Pfeiffer RM, Katzmann JA, Caporaso NE, Hayes RB, et al. Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study. Blood. 2009;113(22):5412–7.CrossRef Landgren O, Kyle RA, Pfeiffer RM, Katzmann JA, Caporaso NE, Hayes RB, et al. Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study. Blood. 2009;113(22):5412–7.CrossRef
3.
Zurück zum Zitat Rajkumar SV, Landgren O, Mateos MV. Smoldering multiple myeloma. Blood. 2015;125(20):3069–75.CrossRef Rajkumar SV, Landgren O, Mateos MV. Smoldering multiple myeloma. Blood. 2015;125(20):3069–75.CrossRef
4.
Zurück zum Zitat Wu V, Moshier E, Leng S, Barlogie B, Cho HJ, Jagannath S, et al. Risk stratification of smoldering multiple myeloma: predictive value of free light chains and group-based trajectory modeling. Blood Adv. 2018;2(12):1470–9.CrossRef Wu V, Moshier E, Leng S, Barlogie B, Cho HJ, Jagannath S, et al. Risk stratification of smoldering multiple myeloma: predictive value of free light chains and group-based trajectory modeling. Blood Adv. 2018;2(12):1470–9.CrossRef
5.
Zurück zum Zitat Kunacheewa C, Manasanch EE. High-risk smoldering myeloma versus early detection of m myeloma: current models, goals of therapy, and clinical implications. Best Pract Res Clin Haematol. 2020;33(1):101152.CrossRef Kunacheewa C, Manasanch EE. High-risk smoldering myeloma versus early detection of m myeloma: current models, goals of therapy, and clinical implications. Best Pract Res Clin Haematol. 2020;33(1):101152.CrossRef
6.
Zurück zum Zitat Cavo M, Terpos E, Nanni C, Moreau P, Lentzsch S, Zweegman S, et al. Role of (18)F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group. Lancet Oncol. 2017;18(4):e206–17.CrossRef Cavo M, Terpos E, Nanni C, Moreau P, Lentzsch S, Zweegman S, et al. Role of (18)F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group. Lancet Oncol. 2017;18(4):e206–17.CrossRef
7.
Zurück zum Zitat Kapoor P, Rajkumar SV. Smoldering multiple myeloma: to treat or not to treat. Cancer J. 2019;25(1):65–71.CrossRef Kapoor P, Rajkumar SV. Smoldering multiple myeloma: to treat or not to treat. Cancer J. 2019;25(1):65–71.CrossRef
8.
Zurück zum Zitat Boutin RD, Bamrungchart S, Bateni CP, Beavers DP, Beavers KM, Meehan JP, et al. CT of patients with hip fracture: muscle size and attenuation help predict mortality. AJR Am J Roentgenol. 2017;208(6):W208–15.CrossRef Boutin RD, Bamrungchart S, Bateni CP, Beavers DP, Beavers KM, Meehan JP, et al. CT of patients with hip fracture: muscle size and attenuation help predict mortality. AJR Am J Roentgenol. 2017;208(6):W208–15.CrossRef
9.
Zurück zum Zitat Joglekar S, Nau PN, Mezhir JJ. The impact of sarcopenia on survival and complications in surgical oncology: a review of the current literature. J Surg Oncol. 2015;112(5):503–9.CrossRef Joglekar S, Nau PN, Mezhir JJ. The impact of sarcopenia on survival and complications in surgical oncology: a review of the current literature. J Surg Oncol. 2015;112(5):503–9.CrossRef
10.
Zurück zum Zitat Zamagni E, Nanni C, Gay F, Pezzi A, Patriarca F, Bello M, et al. 18F-FDG PET/CT focal, but not osteolytic, lesions predict the progression of smoldering myeloma to active disease. Leukemia. 2016;30(2):417–22.CrossRef Zamagni E, Nanni C, Gay F, Pezzi A, Patriarca F, Bello M, et al. 18F-FDG PET/CT focal, but not osteolytic, lesions predict the progression of smoldering myeloma to active disease. Leukemia. 2016;30(2):417–22.CrossRef
11.
Zurück zum Zitat Siontis B, Kumar S, Dispenzieri A, Drake MT, Lacy MQ, Buadi F, et al. Positron emission tomography-computed tomography in the diagnostic evaluation of smoldering multiple myeloma: identification of patients needing therapy. Blood Cancer J. 2015;5:e364.CrossRef Siontis B, Kumar S, Dispenzieri A, Drake MT, Lacy MQ, Buadi F, et al. Positron emission tomography-computed tomography in the diagnostic evaluation of smoldering multiple myeloma: identification of patients needing therapy. Blood Cancer J. 2015;5:e364.CrossRef
12.
Zurück zum Zitat Anderson KC, Alsina M, Atanackovic D, Biermann JS, Chandler JC, Costello C, et al. NCCN guidelines insights: multiple myeloma, version 3.2016. J Natl Compr Cancer Netw. 2016;14(4):389–400.CrossRef Anderson KC, Alsina M, Atanackovic D, Biermann JS, Chandler JC, Costello C, et al. NCCN guidelines insights: multiple myeloma, version 3.2016. J Natl Compr Cancer Netw. 2016;14(4):389–400.CrossRef
13.
Zurück zum Zitat Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos MV, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15(12):e538–48.CrossRef Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos MV, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15(12):e538–48.CrossRef
14.
Zurück zum Zitat Kalichman L, Klindukhov A, Li L, Linov L. Indices of paraspinal muscles degeneration: reliability and association with facet joint osteoarthritis: feasibility study. Clin Spine Surg. 2016;29(9):465–70.CrossRef Kalichman L, Klindukhov A, Li L, Linov L. Indices of paraspinal muscles degeneration: reliability and association with facet joint osteoarthritis: feasibility study. Clin Spine Surg. 2016;29(9):465–70.CrossRef
15.
Zurück zum Zitat Miller BS, Ignatoski KM, Daignault S, Lindland C, Gauger PG, Doherty GM, et al. A quantitative tool to assess degree of sarcopenia objectively in patients with hypercortisolism. Surgery. 2011;150(6):1178–85.CrossRef Miller BS, Ignatoski KM, Daignault S, Lindland C, Gauger PG, Doherty GM, et al. A quantitative tool to assess degree of sarcopenia objectively in patients with hypercortisolism. Surgery. 2011;150(6):1178–85.CrossRef
16.
Zurück zum Zitat Prado CM, Lieffers JR, McCargar LJ, Reiman T, Sawyer MB, Martin L, et al. Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study. Lancet Oncol. 2008;9(7):629–35.CrossRef Prado CM, Lieffers JR, McCargar LJ, Reiman T, Sawyer MB, Martin L, et al. Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study. Lancet Oncol. 2008;9(7):629–35.CrossRef
17.
Zurück zum Zitat Shachar SS, Deal AM, Weinberg M, Nyrop KA, Williams GR, Nishijima TF, et al. Skeletal muscle measures as predictors of toxicity, hospitalization, and survival in patients with metastatic breast cancer receiving taxane-based chemotherapy. Clin Cancer Res. 2017;23(3):658–65.CrossRef Shachar SS, Deal AM, Weinberg M, Nyrop KA, Williams GR, Nishijima TF, et al. Skeletal muscle measures as predictors of toxicity, hospitalization, and survival in patients with metastatic breast cancer receiving taxane-based chemotherapy. Clin Cancer Res. 2017;23(3):658–65.CrossRef
18.
Zurück zum Zitat Shachar SS, Deal AM, Weinberg M, Williams GR, Nyrop KA, Popuri K, et al. Body composition as a predictor of toxicity in patients receiving anthracycline and taxane-based chemotherapy for early-stage breast cancer. Clin Cancer Res. 2017;23(14):3537–43.CrossRef Shachar SS, Deal AM, Weinberg M, Williams GR, Nyrop KA, Popuri K, et al. Body composition as a predictor of toxicity in patients receiving anthracycline and taxane-based chemotherapy for early-stage breast cancer. Clin Cancer Res. 2017;23(14):3537–43.CrossRef
19.
Zurück zum Zitat R Core Team. R: a language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing 2017. R Core Team. R: a language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing 2017.
20.
Zurück zum Zitat Therneau T. A package for survival analysis in S. 2.3.8 ed 2015. Therneau T. A package for survival analysis in S. 2.3.8 ed 2015.
21.
Zurück zum Zitat Cherry BM, Korde N, Kwok M, Manasanch EE, Bhutani M, Mulquin M, et al. Modeling progression risk for smoldering multiple myeloma: results from a prospective clinical study. Leuk Lymphoma. 2013;54(10):2215–8.CrossRef Cherry BM, Korde N, Kwok M, Manasanch EE, Bhutani M, Mulquin M, et al. Modeling progression risk for smoldering multiple myeloma: results from a prospective clinical study. Leuk Lymphoma. 2013;54(10):2215–8.CrossRef
22.
Zurück zum Zitat Miguel JS, Mateos M-V, Gonzalez V, Dimopoulos MA, Kastritis E, Hajek R, et al. Updated risk stratification model for smoldering multiple myeloma (SMM) incorporating the revised IMWG diagnostic criteria. J Clin Oncol. 2019;37(15_suppl):8000.CrossRef Miguel JS, Mateos M-V, Gonzalez V, Dimopoulos MA, Kastritis E, Hajek R, et al. Updated risk stratification model for smoldering multiple myeloma (SMM) incorporating the revised IMWG diagnostic criteria. J Clin Oncol. 2019;37(15_suppl):8000.CrossRef
23.
Zurück zum Zitat Mateos MV, Hernandez MT, Giraldo P, de la Rubia J, de Arriba F, Corral LL, et al. Lenalidomide plus dexamethasone versus observation in patients with high-risk smouldering multiple myeloma (QuiRedex): long-term follow-up of a randomised, controlled, phase 3 trial. Lancet Oncol. 2016;17(8):1127–36.CrossRef Mateos MV, Hernandez MT, Giraldo P, de la Rubia J, de Arriba F, Corral LL, et al. Lenalidomide plus dexamethasone versus observation in patients with high-risk smouldering multiple myeloma (QuiRedex): long-term follow-up of a randomised, controlled, phase 3 trial. Lancet Oncol. 2016;17(8):1127–36.CrossRef
24.
Zurück zum Zitat Lonial S, Jacobus S, Fonseca R, Weiss M, Kumar S, Orlowski RZ, et al. Randomized trial of lenalidomide versus observation in smoldering multiple myeloma. J Clin Oncol. 2020;38(11):1126–37.CrossRef Lonial S, Jacobus S, Fonseca R, Weiss M, Kumar S, Orlowski RZ, et al. Randomized trial of lenalidomide versus observation in smoldering multiple myeloma. J Clin Oncol. 2020;38(11):1126–37.CrossRef
25.
Zurück zum Zitat Veld J, O'Donnell EK, Reagan MR, Yee AJ, Torriani M, Rosen CJ, et al. Abdominal adipose tissue in MGUS and multiple myeloma. Skelet Radiol. 2016;45(9):1277–83.CrossRef Veld J, O'Donnell EK, Reagan MR, Yee AJ, Torriani M, Rosen CJ, et al. Abdominal adipose tissue in MGUS and multiple myeloma. Skelet Radiol. 2016;45(9):1277–83.CrossRef
26.
Zurück zum Zitat Takahashi MES, Mosci C, Souza EM, Brunetto SQ, Etchebehere E, Santos AO, et al. Proposal for a quantitative (18)F-FDG PET/CT metabolic parameter to assess the intensity of bone involvement in multiple myeloma. Sci Rep. 2019;9(1):16429.CrossRef Takahashi MES, Mosci C, Souza EM, Brunetto SQ, Etchebehere E, Santos AO, et al. Proposal for a quantitative (18)F-FDG PET/CT metabolic parameter to assess the intensity of bone involvement in multiple myeloma. Sci Rep. 2019;9(1):16429.CrossRef
27.
Zurück zum Zitat Cengiz A, Arda HU, Doger F, Yavasoglu I, Yurekli Y, Bolaman AZ. Correlation between baseline 18F-FDG PET/CT findings and CD38- and CD138-expressing myeloma cells in bone marrow and clinical parameters in patients with multiple myeloma. Turk J Haematol. 2018;35(3):175–80.PubMedPubMedCentral Cengiz A, Arda HU, Doger F, Yavasoglu I, Yurekli Y, Bolaman AZ. Correlation between baseline 18F-FDG PET/CT findings and CD38- and CD138-expressing myeloma cells in bone marrow and clinical parameters in patients with multiple myeloma. Turk J Haematol. 2018;35(3):175–80.PubMedPubMedCentral
28.
Zurück zum Zitat Manasanch EE, Salem DA, Yuan CM, Tageja N, Bhutani M, Kwok M, et al. Flow cytometric sensitivity and characteristics of plasma cells in patients with multiple myeloma or its precursor disease: influence of biopsy site and anticoagulation method. Leuk Lymphoma. 2015;56(5):1416–24.CrossRef Manasanch EE, Salem DA, Yuan CM, Tageja N, Bhutani M, Kwok M, et al. Flow cytometric sensitivity and characteristics of plasma cells in patients with multiple myeloma or its precursor disease: influence of biopsy site and anticoagulation method. Leuk Lymphoma. 2015;56(5):1416–24.CrossRef
29.
Zurück zum Zitat Zhou C, Foster B, Hagge R, Foster C, Lenchik L, Chaudhari AJ, et al. Opportunistic body composition evaluation in patients with esophageal adenocarcinoma: association of survival with (18)F-FDG PET/CT muscle metrics. Ann Nucl Med. 2020;34(3):174–81.CrossRef Zhou C, Foster B, Hagge R, Foster C, Lenchik L, Chaudhari AJ, et al. Opportunistic body composition evaluation in patients with esophageal adenocarcinoma: association of survival with (18)F-FDG PET/CT muscle metrics. Ann Nucl Med. 2020;34(3):174–81.CrossRef
30.
Zurück zum Zitat Kjonigsen LJ, Harneshaug M, Flotten AM, Karterud LK, Petterson K, Skjolde G, et al. Reproducibility of semiautomated body composition segmentation of abdominal computed tomography: a multiobserver study. Eur Radiol Exp. 2019;3(1):42.CrossRef Kjonigsen LJ, Harneshaug M, Flotten AM, Karterud LK, Petterson K, Skjolde G, et al. Reproducibility of semiautomated body composition segmentation of abdominal computed tomography: a multiobserver study. Eur Radiol Exp. 2019;3(1):42.CrossRef
31.
Zurück zum Zitat Ozola-Zalite I, Mark EB, Gudauskas T, Lyadov V, Olesen SS, Drewes AM, et al. Reliability and validity of the new VikingSlice software for computed tomography body composition analysis. Eur J Clin Nutr. 2019;73(1):54–61.CrossRef Ozola-Zalite I, Mark EB, Gudauskas T, Lyadov V, Olesen SS, Drewes AM, et al. Reliability and validity of the new VikingSlice software for computed tomography body composition analysis. Eur J Clin Nutr. 2019;73(1):54–61.CrossRef
32.
Zurück zum Zitat van Vugt JL, Levolger S, Gharbharan A, Koek M, Niessen WJ, Burger JW, et al. A comparative study of software programmes for cross-sectional skeletal muscle and adipose tissue measurements on abdominal computed tomography scans of rectal cancer patients. J Cachexia Sarcopenia Muscle. 2017;8(2):285–97.CrossRef van Vugt JL, Levolger S, Gharbharan A, Koek M, Niessen WJ, Burger JW, et al. A comparative study of software programmes for cross-sectional skeletal muscle and adipose tissue measurements on abdominal computed tomography scans of rectal cancer patients. J Cachexia Sarcopenia Muscle. 2017;8(2):285–97.CrossRef
33.
Zurück zum Zitat Boutin RD, Katz JR, Chaudhari AJ, Yabes JG, Hirschbein JS, Nakache Y-P, et al. Association of adipose tissue and skeletal muscle metrics with overall survival and postoperative complications in soft tissue sarcoma patients: an opportunistic study using computed tomography. Quant Imaging Med Surg. 2020. http://qims.amegroups.com/article/view/38772 Boutin RD, Katz JR, Chaudhari AJ, Yabes JG, Hirschbein JS, Nakache Y-P, et al. Association of adipose tissue and skeletal muscle metrics with overall survival and postoperative complications in soft tissue sarcoma patients: an opportunistic study using computed tomography. Quant Imaging Med Surg. 2020. http://​qims.​amegroups.​com/​article/​view/​38772
Metadaten
Titel
Marrow uptake on FDG PET/CT is associated with progression from smoldering to symptomatic multiple myeloma
verfasst von
Behrang Amini
Yves-Paul N. Nakache
Lorenzo Nardo
Elisabet E. Manasanch
Jia Sun
Leon Lenchik
Robert D. Boutin
Publikationsdatum
03.07.2020
Verlag
Springer Berlin Heidelberg
Erschienen in
Skeletal Radiology / Ausgabe 1/2021
Print ISSN: 0364-2348
Elektronische ISSN: 1432-2161
DOI
https://doi.org/10.1007/s00256-020-03529-2

Weitere Artikel der Ausgabe 1/2021

Skeletal Radiology 1/2021 Zur Ausgabe

Screening-Mammografie offenbart erhöhtes Herz-Kreislauf-Risiko

26.04.2024 Mammografie Nachrichten

Routinemäßige Mammografien helfen, Brustkrebs frühzeitig zu erkennen. Anhand der Röntgenuntersuchung lassen sich aber auch kardiovaskuläre Risikopatientinnen identifizieren. Als zuverlässiger Anhaltspunkt gilt die Verkalkung der Brustarterien.

S3-Leitlinie zu Pankreaskrebs aktualisiert

23.04.2024 Pankreaskarzinom Nachrichten

Die Empfehlungen zur Therapie des Pankreaskarzinoms wurden um zwei Off-Label-Anwendungen erweitert. Und auch im Bereich der Früherkennung gibt es Aktualisierungen.

Fünf Dinge, die im Kindernotfall besser zu unterlassen sind

18.04.2024 Pädiatrische Notfallmedizin Nachrichten

Im Choosing-Wisely-Programm, das für die deutsche Initiative „Klug entscheiden“ Pate gestanden hat, sind erstmals Empfehlungen zum Umgang mit Notfällen von Kindern erschienen. Fünf Dinge gilt es demnach zu vermeiden.

„Nur wer sich gut aufgehoben fühlt, kann auch für Patientensicherheit sorgen“

13.04.2024 Klinik aktuell Kongressbericht

Die Teilnehmer eines Forums beim DGIM-Kongress waren sich einig: Fehler in der Medizin sind häufig in ungeeigneten Prozessen und mangelnder Kommunikation begründet. Gespräche mit Patienten und im Team können helfen.

Update Radiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.